SPY337.71+0.27 0.08%
DIA279.56-0.49 -0.17%
IXIC11,097.73+85.49 0.78%

RBC Capital Maintains Outperform on Amedisys, Raises Price Target to $260

RBC Capital maintains Amedisys (NASDAQ:AMED) with a Outperform and raises the price target from $218 to $260.

Benzinga · -
RBC Capital maintains Amedisys (NASDAQ: AMED) with a Outperform and raises the price target from $218 to $260.